Supplementary materials: Cost–effectiveness and cost–benefit analysis of oliceridine in the treatment of acute pain

<b>These are peer-reviewed supplementary tables for the article '</b><b>Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain</b><b>' published in the </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Supplementary Table 1.</b> Estimated mean and median cost and length of stay (LOS) derived from the 2017 National Inpatient Sample-Healthcare Cost and Utilization Project (NIS-HCUP) dataset.<b>Supplementary Table 2. </b>Estimated cost weights for opioid-induced respiratory depression events by type of surgery (in 2017 US dollars).<b>Supplementary Table 3. </b>Health economic model cost weights for opioid-induced respiratory depression, vomiting, and somnolence inflated to 2020 US dollar costs.<b>Supplementary Table 4. </b>Base model estimates: Summary of impact of sensitivity analyses on the base model estimates.<b>Supplementary Table 5. </b>Oliceridine parameter values used in the Monte Carlo simulations (values for morphine parameters were similarly varied).<b>Summary: </b><b>Aim</b>: Oliceridine, a new class of μ-opioid receptor agonist, is selective for G-protein signaling (analgesia) with limited recruitment of β-arrestin (associated with adverse outcomes) and may provide a cost-effective alternative versus conventional opioid morphine for postoperative pain. <b>Patients &amp; methods</b>: Using a decision tree with a 24-h time horizon, we calculated costs for medication and management of three most common adverse events (AEs; oxygen saturation &lt;90%, vomiting and somnolence) following postoperative oliceridine or morphine use.<b> Results</b>: Using oliceridine, the cost for managing AEs was US$528,424 versus $852,429 for morphine, with a net cost savings of $324,005. <b>Conclusion</b>: Oliceridine has a favorable overall impact on the total cost of postoperative care compared with the use of the conventional opioid morphine.